MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Tuesday, February 9, 2010

Multiple Sclerosis Experts Join Biogen Idec's Research and Development Team

CAMBRIDGE, Mass., Feb 08, 2010 (BUSINESS WIRE) -- Biogen Idec a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced that John R. Richert, M.D., will be joining the Company as a Senior Fellow in Neurology Research and Development and Nancy D. Richert, M.D., Ph.D., will be joining as a Fellow in Neurology Research and Development.

"We are extremely excited to add these two very distinguished leaders in the multiple sclerosis community to the Biogen Idec team," said Alfred Sandrock, M.D., Ph.D., Senior Vice President, Neurology Research and Development. "Drs. John and Nancy Richert have a wealth of experience in MS treatment and research, which will help shape our drug development strategies and further enhance our abilities to bring to market innovative therapies that improve patients' lives."

"I've spent my professional life working on advancing the treatment of multiple sclerosis and am thrilled to be joining the talented and dedicated team at Biogen Idec," said Dr. John Richert. "Biogen Idec is a leader in the treatment of multiple sclerosis, and I look forward to working with the Company to further their research for this debilitating disease."

"Neuroimaging is a rapidly advancing discipline that has become an indispensable tool in the diagnosis and treatment of multiple sclerosis and other neurological disorders," said Dr. Nancy Richert. "I'm excited to apply my expertise to help Biogen Idec further its mission of developing life-saving and life-altering therapies for patients with multiple sclerosis, Alzheimer's, Parkinson's and other serious neurological diseases."

Dr. John Richert joins Biogen Idec from the National Multiple Sclerosis Society (NMSS), where he served as executive vice president for Research and Clinical Programs for the past five years.

Continue reading

######################

Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you
.

============================================

1 comment:

Lauren said...

Considering Dr. John Richert's affiliation with the NMSS at the time of the Tysabri hearings before the FDA AC Committee back in March 2006 when he was going to testify against Tysabri's reapproval, indicating that Tysabri needed more trial time & suggested that most MS patients could not cognitively make an informed choice about the risk of PML-which is absurd, most of us had to challenge the NMSS just to have Dr. Richert's "biased opinion" posted on their website, and had to fight even harder to have his opinion changed to a more balanced opinion of Tysabri, even though a lot of MS patients had been waiting over 18 months for its return.

I find it interesting that Biogen would hire such a numbskull, because in my opinion, ,Dr. Richert would have put more patients at risk for having further relapses & accumulating disabilities , should Tysabri not have been returned to the market when it was. In my mind, Dr. Richert has no business working for Biogen, sad-really sad,

Lauren :/